Short Interest in Integrated BioPharma, Inc. (OTCMKTS:INBP) Rises By 1,700.0%

Integrated BioPharma, Inc. (OTCMKTS:INBPGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,800 shares, a growth of 1,700.0% from the March 31st total of 100 shares. Based on an average trading volume of 19,000 shares, the short-interest ratio is currently 0.1 days.

INBP traded down $0.09 on Wednesday, reaching $0.72. The company had a trading volume of 71,674 shares, compared to its average volume of 14,095. The company has a fifty day moving average of $0.84 and a 200-day moving average of $0.96. The company has a market capitalization of $21.51 million, a P/E ratio of 3.13 and a beta of 0.27. Integrated BioPharma has a one year low of $0.27 and a one year high of $1.25.

Integrated BioPharma (OTCMKTS:INBPGet Rating) last announced its earnings results on Thursday, February 10th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $14.59 million during the quarter. Integrated BioPharma had a net margin of 11.87% and a return on equity of 53.01%.

Integrated BioPharma Company Profile (Get Rating)

Integrated BioPharma, Inc, together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments.

Featured Articles

Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.